Tesamorelin 10mg kit

Description

Tesamorelin is a synthetic peptide analog of human growth hormone-releasing hormone, structurally based on the biologically active
1–44 amino-acid sequence of endogenous GHRH. Its N-terminus contains a trans-3-hexenoic acid modification, a structural feature associated with improved resistance to enzymatic degradation relative to unmodified GHRH. This molecular design makes Tesamorelin a valuable reference compound for biochemical, receptor-binding, and peptide-stability research.

The primary molecular target of Tesamorelin is the growth hormone-releasing hormone receptor (GHRH-R), a class B G protein-coupled receptor expressed predominantly on pituitary somatotroph cells. Receptor engagement is associated with activation of adenylate cyclase and increased intracellular cyclic adenosine monophosphate (cAMP) signaling. Downstream signaling may involve protein kinase A activity, calcium-dependent processes, transcriptional regulation, and pathways relevant to growth hormone synthesis and release.

In laboratory research, Tesamorelin is relevant to studies of hypothalamic-pituitary signaling, GHRH receptor pharmacology, peptide receptor selectivity, endocrine feedback systems, and growth hormone/insulin-like growth factor axis biology. It may also support analytical method development, including peptide identity testing, purity assessment, stability studies, and receptor-based assay validation.

Its defined amino-acid composition and modified N-terminal structure provide researchers with a useful model for examining how peptide engineering can affect receptor activity, proteolytic stability, and pharmacodynamic signaling profiles. Tesamorelin is therefore of scientific interest in endocrinology, molecular pharmacology, peptide chemistry, and cell-signaling research.